AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02555696 — intervention group
Intervention type: DRUG
Intervention: nab-paclitaxel
Description: nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity
Study NCT03298672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NDX-1017
Description: Solution of NDX-1017 for subcutaneous injection
Study NCT03298672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for subcutaneous injection
Study NCT01791647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin 1500 mg
Study NCT01791647 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: myoinositol 1500 mg
Study NCT00074022 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GTI-2040
Description: Given IV
Study NCT00074022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00074022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00074022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00891319 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulator
Description: • 12-week intervention~1. Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)~2. Self-administered CCFES or cNMES-mediated hand opening exercise performed 10 sessions per week at home.
Study NCT00891319 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulator
Description: • 12-week intervention~1. Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)~2. Self-administered CCFES or cNMES-mediated hand opening exercise performed 10 sessions per week at home.
Study NCT01516151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CaPre™
Description: 1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks
Study NCT01516151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CaPre™
Description: 1 capsule of 1.0g total CaPre™ for 4 weeks followed by two 1.0g capsules per day for an additional 4 weeks
Study NCT01516151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CaPre™
Description: 2 capsules of 1.0g total CaPre™ for 4 weeks followed by 4 capsules of 1.0g total per day for an additional 4 weeks.
Study NCT01516151 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lipid Lowering Medication
Description: Patient will be treated as per the Standard of care.
Study NCT01516151 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: CaPre™
Description: 4 capsules of 1 g total per day for 8 weeks.
Study NCT00407589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOL-303224-A
Description: 1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).
Study NCT04363073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Annabella Breast Pump
Description: Milk will be expressed using Annabella breast pump for 4 consecutive days (at least 24h apart)
Study NCT04363073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Breast Pump
Description: Milk will be expressed using Control breast pump for 4 consecutive days (at least 24h apart)
Study NCT04020939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPY imaging
Description: Use of the SPY Pinpoint imaging device to evaluate intraoperative intestinal perfusion in children.
Study NCT04020939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Intravenous injection of indocyanine green to evaluate the intestinal perfusion.
Study NCT02462213 — intervention group
Intervention type: OTHER
Intervention: Amyloidosis
Description: Patients with amyloidosis without cardiac involvement will undergo cardiac MRI and possible biochemical analysis during the course of the study.
Study NCT02462213 — intervention group
Intervention type: OTHER
Intervention: Cardiac Amyloidosis
Description: Patients with confirmed cardiac amyloidosis will undergo cardiac MRI and possible biochemical analysis during the course of the study.
Study NCT02470026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: yohimbine
Description: single low dose treatment
Study NCT02470026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: single control treatment
Study NCT02486848 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Topical Minoxidil Solution
Description: 5% Topical Minoxidil Solution
Study NCT02486848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 15% Topical Minoxidil Solution
Description: 15% Topical Minoxidil Solution
Study NCT00626756 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LiDCO technology
Description: non invasive monitoring of cardiac output
Study NCT03878446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somapacitan
Description: Somapacitan injected under the skin once a week.
Study NCT00445913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: control dendritic cells
Description: The dendritic cells will be treated ex vivo with vehicle and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to these control dendritic cells will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
Study NCT01540552 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Study NCT01540552 — intervention group
Intervention type: PROCEDURE
Intervention: computed tomography
Study NCT01540552 — intervention group
Intervention type: PROCEDURE
Intervention: computer-aided detection/diagnosis
Study NCT03228225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele Cardiac Rehabilitation
Description: Comprehensive intervention according to the secondary prevention goals
Study NCT01263197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: administered orally
Study NCT01263197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol
Description: administered orally
Study NCT03878446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norditropin®
Description: Norditropin® injected under the skin once a day.
Study NCT03386513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN632
Description: CD123-targeted ADC
Study NCT04622046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2060
Description: ALXN2060 tablets will be administered twice daily at a dose of 800 milligrams.
Study NCT01263197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: administered orally
Study NCT06735937 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low flow anesthesia
Description: Anesthesia management by using low flow anesthesia
Study NCT03292289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre- and post-operative consultation
Description: Before and between the two interventions
Study NCT03292289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stomatherapy consultation
Description: Clinical exam. At one and six months after the 2nd intervention
Study NCT03292289 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: * QLQ-C30 and QLQ-CR29 at each time defined by the study (one month before and after the first intervention, before the 2nd intervention and at 1, 3, 6 and 12 months after the 2nd intervention)~* Stoma-QoL before and after the 2nd intervention~* LARS score at 1, 3, 6 and 12 months after the 2nd intervention
Study NCT01125943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholine
Description: Intra-arterial infusion
Study NCT01125943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroprusside
Description: Intra arterial infusion
Study NCT01125943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intra arterial infusion
Study NCT04308824 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clipping
Description: a single clip will be placed in every case of polypectomy for large colorectal polyps
Study NCT04308824 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nebulization of glue
Description: After clipping, a cyanoacrilate glue will be nebulized using a spray catheter
Study NCT02296151 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluteus medius strengthening
Description: Hip abductor, gluteus medius strengthening
Study NCT02296151 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gluteus medius strengthening
Description: Hip abductor, gluteus medius strengthening
Study NCT02296151 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: iliotibial band stretches
Description: Iliotibial band stretches
Study NCT03219320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NYX-2925
Description: NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
Study NCT03219320 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo capsules.
Study NCT01865396 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interventional palliative care
Description: Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.
Study NCT01865396 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard oncologic care
Description: Patients will receive standard oncologic care.
Study NCT02567539 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT with or without radiosensitive therapy
Description: Re-irradiation with hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc
Study NCT02567539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiosensitive therapy
Description: Radiosensitive therapy with Temozolomide
Study NCT00594516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) Immediate Release IR
Description: 21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
Study NCT00594516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) Extended Release (ER)
Description: During 2 double blind periods: Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
Study NCT00594516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tapentadol (CG5503) Immediate Release (IR)
Description: Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second
Study NCT03426787 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Participants will have the option to view a web or paper-based version of the decision aid.
Study NCT02682225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous placebo
Description: Participants will receive placebo, 40-minute, intravenous infusion on Day 1 of Sequence 1, on Day 2 of Sequence 2, on Day 1 of Period 1 in Sequence 3, 5 and 6, on Day 1 of Period 2 in Sequence 3, 4 and 6, on Day 1 of Period 3 in Sequence 4, 5 and 6, and on Day 1 of Period 4 in Sequence 3, 4 and 5.
Study NCT01263197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for LY2216684
Description: administered orally
Study NCT02682225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal placebo
Description: Participants will receive placebo, intranasally, on Day 1 or Day 2 in Sequence 1 and 2, on Day 1 of Period 1 in Sequence 3 and 4, on Day 1 of Period 2 in Sequence 4 and 5, on Day 1 of Period 3 in Sequence 3 and 6 and on Day 1 of Period 4 in Sequence 5 and 6.
Study NCT02682225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous racemic ketamine
Description: Participants will receive 0.5 mg/kg racemic ketamine, intranasally, on Day 2 in sequence 1, on Day 1 in sequence 2, on Day 1 of Period 1 in Sequence 4, on Day 1 of Period 2 in Sequence 5, on Day 1 of Period 3 in Sequence 3, and on Day 1 of Period 4 in Sequence 6.
Study NCT02682225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 112 mg
Description: Participants will receive 112 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 6, on Day 1 of Period 2 in Sequence 3, on Day 1 of Period 3 in Sequence 5, and on Day 1 of Period 4 in Sequence 4.
Study NCT02682225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 84 mg
Description: Participants will receive 84 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 5, on Day 1 of Period 2 in Sequence 6, on Day 1 of Period 3 in Sequence 4, and on Day 1 of Period 4 in Sequence 3.
Study NCT03998176 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide
Description: B/F/TAF single tablet formulation
Study NCT04662398 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JT Device
Description: Shocker giving electrical shocks on testes
Study NCT04662398 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: JT Device
Description: Shocker giving electrical shocks on testes
Study NCT01191372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo control
Description: sterile saline for injection
Study NCT01191372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARC19499
Description: Anti-tissue factor pathway inhibitor (TFPI) aptamer
Study NCT03662139 — intervention group
Intervention type: OTHER
Intervention: Dynamic Gait Index
Description: Dynamic Gait Index is a clinical tool for assessing functional balance and gait variability in people with neurologic conditions
Study NCT01226823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: 300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
Study NCT01226823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
Study NCT01131949 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Tablets (chewable, dispersible), 25 mg
Study NCT01131949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Tablets (chewable, dispersible), 25 mg
Study NCT04398511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L brevis
Description: Lactobacillus brevis CD2 lozenges (4 billion CFU) after breakfast, lunch and dinner for 21 days.
Study NCT04398511 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lozenges after breakfast, lunch and dinner for 21 days.
Study NCT00288977 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Islet Infusion
Study NCT02598609 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Education program for NICU caregivers
Description: * standardized educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it (compulsory)~* implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a daily goals bundle and checklist. (compulsory)~* poster for prevention of extravasation injuries
Study NCT02992886 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Preoperative radiation
Description: Radiation treatment before surgery
Study NCT02992886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltitrexed
Description: concurrent chemotherapy
Study NCT02992886 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic surgery
Study NCT03846739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin nasal spray
Description: Intranasal administration, 6, 12, or 24 international units (IU) oxytocin.
Study NCT03846739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The placebo nasal sprays contain identical ingredients except for the peptide itself.
Study NCT01580150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Berries
Description: Meals containing starch (bread) or sucrose are consumed with berries (150 g) or berry nectars (300 mL).
Study NCT01580150 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No berries
Description: Meals containing starch (bread) or sucrose are consumed without berries.
Study NCT00298168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YSPSL
Description: YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
Study NCT00298168 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
Study NCT00298168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YSPSL
Description: YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 10 mg YSPSL in 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
Study NCT00244972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00244972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO
Study NCT00244972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO
Study NCT02464228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: oral
Study NCT00908583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plasmapheresis
Description: Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
Study NCT00908583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Patients will receive bortezomib as described in protocol
Study NCT01263197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for albuterol
Description: administered orally
Study NCT01263197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo for propranolol
Description: administered orally
Study NCT03524976 — intervention group
Intervention type: DEVICE
Intervention: Squid
Description: SQUID™ is injected into the vascular site to be treated, under fluoroscopic control. DMSO dissipates in the blood and causes precipitation of EVOH in which the tantalum powder is trapped. It then forms a consistent spongy embolus.~This embolus solidifies from the outside inwardly while moving distally in the vessel. The non-adhesive character of the embolus allows slow and controlled injections while leaving in place the microcatheter.
Study NCT01055197 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prophylactic Cranial Irradiation
Description: Prophylactic Cranial Irradiation (PCI) to the brain in ten once-daily fractions of 2.5 Gy, five days per week, for a total of 25 Gy.
Study NCT01055197 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation Therapy (RT) to locoregional and residual metastatic disease in 15 once daily fractions of 3.0 Gy, 5 days per week, for a total of 45 Gy
Study NCT00908583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will receive rituximab as described in protocol
Study NCT00908583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
Study NCT04110964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAV-hTERT
Description: subjects will receive a single LGT (AAV-hTERT) treatment via IV administration